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A b s t r a c t
Background: Familial hypercholesterolaemia (FH) is the most common genetic disease leading to premature atherosclerosis. 
Aim: The aim of the study was to evaluate the prevalence, diagnosis, and treatment of FH in outpatient practices in Poland.
Methods: The study included a representative sample of 147 primary care physicians, cardiologists, and diabetologists caring 
for 2812 adult patients with hypercholesterolaemia and low-density lipoprotein cholesterol (LDL-C) level > 1.8 mmol/L, who 
were treated with statins or did not receive statins due to intolerance or contraindications. The physicians declared whether 
they diagnosed FH in the study group. In addition, we evaluated the Dutch Lipid Clinic Network (DLCN) diagnostic criteria 
for FH in all patients. The results were weighted and extrapolated to the general outpatient population in Poland. Treatment 
and its effectiveness were also evaluated.
Results: FH6+ score by the DLCN criteria was found in 3.6% of the study group, which translates by extrapolation to 
136,300 adult patients with FH in Poland. Among patients with FH6+, this diagnosis was correctly made by physicians in 
25% of cases and was not established in 75% of cases. Only 32.8% of patients received high statin doses. High LDL-C levels 
were found in a large proportion of patients, including levels ≥ 5.0 mmol/L in 42.7% of patients and ≥ 4.1 mmol/L in 59.7% 
of patients.
Conclusions: Familial hypercholesterolaemia is inadequately diagnosed and treated in Poland, which calls for a radical im-
provement of pre- and postgraduate education in this regard.
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INTRODUCTION
Familial hypercholesterolaemia (FH) is the most common 
genetic disease in the general population, occurring mostly 
in the heterozygotic form (heterozygotic familial hypercholes-
terolaemia, HeFH). The prevalence of FH in Poland has been 
estimated at one in 250 adults [1]. High levels of low-density 
lipoprotein cholesterol (LDL-C) since early life are associated 
with premature ischaemic heart disease [2, 3]. The hetero-
zygotic form, usually inherited from one parent, is mostly 
caused by a mutation in the LDL receptor gene. Less frequent 
causes include apolipoprotein B (apo B) gene mutations, and 
even less frequent are proprotein convertase subtilisin/kexin 
type 9 (PCSK9) gene mutations. For a long time, FH has not 
gained interest among clinicians despite risks of premature 
myocardial infarction and death, as indicated by the title of 
the European Atherosclerosis Society expert panel publica-
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tion, “Familial hypercholesterolaemia is underdiagnosed and 
undertreated in the general population” [3]. It resulted from 
a mistaken belief (based on previous studies) that the disease 
was relatively infrequent, the inability to diagnose it, and the 
lack of available therapeutic options to reduce high LDL-C 
levels to low values that are associated with a lower risk for 
coronary artery disease. Currently, new potent lipid-lowering 
agents combined with statins allow LDL-C level reduction to, 
or close to, the target values in patients with FH [4–6]. This has 
prompted more interest in the diagnosis and treatment of this 
disease and resulted in the publication of multiple manage-
ment guidelines and expert consensus statements [2, 3, 7–10].
It is now possible to achieve low LDL-C levels that have 
been proposed in the European guidelines for the manage-
ment of dyslipidaemia as the therapeutic goals in FH, i.e. 
LDL-C level < 2.6 mmol/L (100 mg/dL) in subjects without 
cardiovascular disease (CVD) and < 1.8 mmol/L (70 mg/dL) 
in those with CVD [8]. Thus, the pathway to improve the 
diagnosis and management of FH might appropriately begin 
with an improved knowledge on the current status of outpa-
tient care of this condition in Poland.
The aim of the Economedica Dyslipidaemia 2015 study 
was to evaluate the prevalence and quality of the diagnosis 
and treatment of at least probable FH in outpatient care in 
Poland, based on a representative sample of physicians (pri-
mary care physicians, cardiologists, and diabetologists) and 
their patients. Our study design allowed: (i) estimation of the 
size of the adult FH patient population under outpatient care 
in Poland; and (ii) extrapolation of our findings regarding the 
diagnosis and treatment of FH to that population.
METHODS
Physician sampling
Physician sampling was based on 12 strata (six geographical 
regions, overall 2–4 voivodeships, according to the classifi-
cation by the Central Statistical Office of Poland, and two 
types of locations based on the physician’s place of work 
— voivodeship capital cities and other locations), taking into 
account the structure of selected physician specialties in the 
Health Data Management database (https://www.farmaprom.
pl/pl/bazy-danych/). To obtain adequate precision of study 
findings among specialists, we intentionally increased the 
number of invited cardiologists and diabetologists in relation 
to primary care physicians, with compensation by appropriate 
weighting during further analyses. Physician recruitment for 
the study was based on quota sampling. We invited 75 pri-
mary care physicians, 45 cardiologists, and 30 diabetologists 
to participate in the study. Overall, 147 physicians agreed to 
participate, including 72 primary care physicians, 45 cardiolo-
gists, and 30 diabetologists. Primary care physicians could be 
recruited for the study if they saw at least 100 patients, and 
cardiologists and diabetologists were considered if they saw 
at least 60 patients during a typical workweek. 
Patient sampling
The study was conducted from June to August 2015. Each par-
ticipating physician recorded all adult patients (aged ≥ 18 years) 
seen within two weeks and identified those with hypercho-
lesterolaemia with LDL-C level > 1.8 mmol/L (70 mg/dL), 
including patients treated with statins for at least six months, 
those who were prescribed with statins at the current visit, and 
those who were not treated with statins due to intolerance 
or contraindications. A questionnaire consisting of two parts, 
A and B, was filled in for the first 20 patients.
Part A of the questionnaire, “Patient characteristics and 
treatment,” included, among others, data on patient age, 
sex, serum lipid profile (total cholesterol, LDL-C, HDL-C, 
and triglyceride levels), including the most recent one and 
the one before initiation of lipid-lowering therapy, use of 
lipid-lowering drugs and their doses, and concomitant condi-
tions including CVD and the date of the last cardiovascular 
event. Thus, the questionnaire included two items that might 
have indicated probable or definite FH, i.e. pre-treatment 
LDL-C level and premature occurrence of coronary artery 
disease or other CVD.
Part B of the questionnaire included information about 
the Dutch Lipid Clinic Network (DLCN) diagnostic criteria 
for FH [2, 3], without actual scoring as per the DLCN score.
Data were collected using the Computer Assisted Web 
Interview (CAWI) technique using an Internet form created 
for the project. A paper form of the questionnaire was used 
if there was no computer access. Patient data were coded 
before being sent to the study administrator, without any 
possibility to decode them.
Based on the answers to the questions in part A of the 
questionnaire, physicians declared whether FH was diagnosed 
in patients and identified the specialty of the physician who 
made the diagnosis. By filling in part B of the questionnaire, 
they also independently provided data on the presence or 
absence of the DLCN diagnostic criteria. Based on the latter 
information, we were able to perform DCLN scoring and 
identify patients with a definite (score > 8) or a probable 
(score 6–8) diagnosis of FH.
Study material
During the study period, the participating physicians saw 
on average 32 patients per day, and within the working 
days of the two-week span covered they saw an average of 
11 patients per day who had indications for lipid-lowering 
treatment for hypercholesterolaemia. Overall, data were 
collected for 2812 patients, including 1349 patients seen by 
primary care physicians, 884 patients seen by cardiologists, 
and 579 patients seen by diabetologists. Due to a server 
failure, part B of the questionnaire was filled in for 2257 pa-
tients, including 1049 patients seen by primary care physi-
cians, 696 patients seen by cardiologists, and 512 patients 
seen by diabetologists.
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Weighting and extrapolation
The number of patients presenting separately to primary 
care physicians, cardiologists, and diabetologists was ap-
praised based on the length of the periods between visits, 
as calculated from the number of days for which the therapy 
was prescribed. The duration of prescribed treatment was 
calculated based on the daily drug dose and the number 
of drug packages prescribed. Because the study recruited 
more cardiologists and diabetologists than would be ap-
propriate based on the nationwide ratio of cardiologists and 
diabetologists to primary care physicians, we performed 
physician post-stratification by applying weights to correct 
the proportion of primary care physicians to cardiologists 
and diabetologists, making it similar to the ratio between 
these specialties in Poland, which is 21:3.4:1 (primary care 
physicians, cardiologists, and diabetologists, respectively). 
During the weighting and extrapolation process, we ad-
ditionally corrected the age structure of the study patients 
based on the data from the RECEPTOmetr Sequence (a com-
mercial continuous data tool for monitoring prescriptions). 
After evaluating of the number of patients presenting to 
primary care physicians, cardiologists, and diabetologists, 
and weighting the results in accordance with the current 
proportions between primary care physicians and special-
ists, we estimated the number of adult patients receiving 
outpatient care from the studied physician specialties, the 
number of patients with hypercholesterolaemia, and the 
number of patients with FH.
All results presented below are weighted and extrapolated 
to the general population. 
Statistical analysis
Statistical analysis was performed using SPSS v. 21.0 (SPSS 
Inc., Chicago, IL, USA) software. To compare the frequency 
of feature occurrence c2 test was carried out, and to com-
pare average values the t test for equality of means was 
performed. When defining statistical significance, a value of 
p < 0.05 (confidence level 0.95) was adopted.
RESULTS
Following the weighting and extrapolation process, our 
study findings indicate that the number of adult patients in 
Poland with LDL-C levels > 1.8 mmol/L and indications for 
lipid-lowering therapy, who receive outpatient care (primary 
care physicians, cardiologists, and diabetologists) can be 
estimated at 3,757,546.
Among 2812 outpatients with LDL-C levels > 1.8 mmol/L, 
who were seen by the study physicians, the criteria of definite 
or probable FH (DLCN score of ≥ 6 [FH6+]) were met by 
95 subjects (49 were reported by primary care physicians, 
36 by cardiologists, and 10 by diabetologists). This amounted 
to 3.6% of the study group, and when extrapolated to the 
general population our findings indicate that the overall num-
ber of adult outpatients with FH in Poland can be estimated 
at 136,300.
The criteria of definite FH (DLCN score of > 8) were met 
by 51 subjects. By extrapolation to the general population, 
this number translates to 2.2%, which means 80,800 adult 
outpatients in Poland.
Out of 95 patients with six or more points on a scale of 
DLCN, 37 were treated with high doses of statins, 63 were 
treated in secondary prevention (at least one of the follow-
ing: unstable coronary artery disease, myocardial infarction 
[STEMI/NSTEMI], ischaemic stroke/transient ischaemic attack, 
coronary revascularisation [CABG/PTCA], ischaemic heart 
disease/stable coronary artery disease, peripheral arterial 
disease), and 31 of them were treated with high statin doses.
Notable characteristics of patients with at least prob-
able FH compared to patients with previously established 
hypercholesterolaemia (without FH) with LDL-C level of 
> 1.8 mmol/L included significantly younger age (57.1 years 
vs. 64.9 years) and significantly higher mean total cholesterol 
and LDL-C levels (6.24 mmol/L [241.4 mg/dL] vs. 5.17 mmol/L 
[200.3 mg/dL] and 4.54 mmol/L [175.4 mg/dL] vs. 2.99 mmol/L 
[115.5 mg/dL], respectively). These data are shown in Table 1.
We also found different rates of diabetes (24.6% 
vs. 34.0%) and hypertension (77.5% vs. 86.5%) between 
patients with FH6+ and the remaining patients. In contrast, 
no clear differences (without standardisation for age) were 
seen in the rates of CVD.
Following age standardisation, CVD was significantly 
more prevalent (p < 0.05) in patients with FH6+ (61.9%) 
compared to the remaining patients (49.1%). Significantly 
higher total cholesterol and LDL-C levels in patients with 
FH6+ were seen also after age standardisation, while the 
differences in the rates of other concomitant conditions, i.e. 
type 2 diabetes and hypertension, were reduced.
In the group of patients with LDL-C levels > 1.8 mmol/L 
and at least probable FH, 85% of patients, after weighting 
and extrapolation, received statin therapy, but less than half 
of them (46.5%) received high statin doses, i.e. rosuvasta-
tin ≥ 20 mg/day or atorvastatin ≥ 40 mg/day. When extrapolat-
ing these data to the general population, as described above 
(3.6% of the study group, translating to 136,000 patients with 
at least probable FH in the general population), it may be 
estimated that 116,000 (85.3%) patients receive statin therapy, 
of which 54,000 patients receive high statin doses. It should 
also be noted that 13,000 (9.6%) patients in this group do not 
receive statin therapy due to intolerance or contraindications.
Among patients with FH6+ and LDL-C levels > 1.8 mmol/L 
during intensive statin therapy, LDL-C level was ≥ 2.6 mmol/L 
(100 mg/dL) in 88.3% of patients, ≥ 4.1 mmol/L in 59.7% of 
patients, and ≥ 5.0 mmol/L in 42.7% of patients receiving 
high doses of potent statins, when extrapolated to the gen-
eral Polish population. It translates to 47,705, 31,944 and 
23,357 patients with FH, respectively (Fig. 1). 
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Among patients with at least probable FH, after weighting 
and extrapolation, more than half (52.5%) are in secondary 
prevention, translating to 71,000 patients in the general 
Polish population. Unfortunately, our findings indicate that 
only three-fourths of them (about 53,000 patients or 74.8%) 
receive statin therapy, and again only three-fourths of them 
(40,000 patients or 74.3%) receive high statin doses.
Among secondary prevention patients with FH6+ 
and LDL-C levels > 1.8 mmol/L during intensive statin 
therapy, after weighting and extrapolation, LDL-C level 
was ≥ 2.6 mmol/L in 85.7% (34,060 patients), ≥ 4.1 mmol/L 
in 52.5% (20,780 patients), and ≥ 5.0 mmol/L in 43.6% 
(17,540 patients) of patients despite use of high statin doses 
(all extrapolated to the general Polish population) (Fig. 2).
In light of the above findings, we also obtained interesting 
data in regard to drug prescription patterns during visits in the 
study period. Despite a high likelihood of FH, a low statin dose 
was prescribed to as many as 45.1% of patients, significantly 
less frequently by cardiologists (15.2% of patients) compared 
to primary care physicians (56.2% of patients). Cardiologists 
Table 1. Patients’ characteristics
Patient profile FH6+ FH6+ after standardisation 
for age in FH6+ group
Remaining patients  
(LDL-C > 1.81 mmol/L)*
Unweighted sample size n = 95 n = 95 n = 2162
Age [years] 57.1 ± 11.6 64.5 ± 10.9 64.9 ± 11.1
Body mass index [kg/m2] 29.4 ± 4.3 29.1 ± 4.3 28.2 ± 4.1
Total cholesterol [mmol/L] 6.24 ± 1.48 6.18 ± 1.53 5.18 ± 1.04
Triglycerides [mmol/L] 2.05 ± 0.85 1.99 ± 0.91 1.61 ± 0.74
LDL-C [mmol/L] 4.54 ± 1.66 4.29 ± 1.58 2.99 ± 0.89
Men 64.6% (88,000) 58.2% (79,000) 46.3% (1,676,000)
Type 2 diabetes 24.6% (34,000) 33.6% (46,000) 34.0% (1,230,000)
Hypertension 77.5% (106,000) 83.1% (113) 86.5% (3,131,000)
Chronic kidney disease 4.0% (6000) 5.4% (7000) 7.7% (279,000)
Smokers in recent quartiles (< 3 months) 26.4% (36,000) 27.2% (37,000) 24.4% (885,000)
Cardiovascular disease** 49.4% (67,000) 61.9% (84,000) 49.1% (1,776,000)
Data are shown as mean ± standard deviation or percentage (number). LDL-C — low-density lipoprotein cholesterol
Patient numbers rounded according to the rule of rounding to the nearest thousand.
*Remaining patients — those with Dutch Lipid Clinic Network score (DLCN) < 6.
**At least one of the following: ischaemic heart disease, myocardial infarction (STEMI/NSTEMI), unstable coronary artery disease, previous  
ischaemic stroke/transient ischaemic attack, coronary revascularisation (CABG/PTCA), peripheral arterial revascularisation, peripheral amputation 
due to atherosclerotic vascular disease.
Figure 1. Distribution of low-density lipoprotein cholesterol (LDL-C) levels (% of patients) in patients with FH6+ treated with 
high-dose statins. Extrapolation of study results to the population of patients with familial hypercholesterolaemia (FH) in Poland 
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prescribed high statin doses to 59.2% of patients with FH6+, 
compared to only 22.9% of such patients seen by primary 
care physicians. Overall, high statin doses were prescribed 
to 32.8% of patients with FH6+. Other therapies, such as 
ezetimibe combined with statins or ezetimibe monotherapy, 
were used in a minority of patients, probably due to the high 
cost of such treatment in the study period (Table 2).
We also analysed diagnoses of FH declared by the study 
physicians. Based on the previous assumptions of about 
3,757,546 adult outpatients with LDL-C levels > 1.8 mmol/L 
in Poland, the diagnosis of FH was declared in about 2.3% 
of study patients, which translates to 88,000 patients in Po-
land. However, an independent objective assessment based 
on the diagnostic criteria for FH confirmed this diagnosis in 
only a subset of these patients, which may be extrapolated 
to 34,000 patients in the general population. False positive 
diagnoses of FH by the study physicians, made in 61% of 
patients in whom the diagnosis of FH was declared by the 
study physicians, translate to 54,000 patients in the general 
population. In contrast, among patients without a diagnosis 
of FH as declared by the study physicians, translating to 
3,349,000 patients in the general population, the diagnosis 
of FH by the DLCN criteria was made in 2.7% of patients, 
translating to 90,400 patients in the general population. 
FH was also diagnosed in 3.6% of patients (translating to 
320,000 patients in the general population) who were re-
ported by the study physicians as not evaluable due to lack of 
data, which translates to 11,500 patients in the general popu-
lation. Overall, this gives 102,000 patients with undiagnosed 
FH in the general population, despite the fact that availability 
of data from personal history, physical examination, family 
history, and lipid profile testing made this diagnosis feasible 
and justified (Fig. 3).
Among patients with at least probable FH based on the 
DLCN criteria, the diagnosis of FH was declared by the study 
physicians in only 25% of cases (including in 25% of patients 
Figure 2. Distribution of low-density lipoprotein cholesterol (LDL-C) levels (% of patients) in patients with FH6+ (secondary  
prevention) with LDL-C levels > 1.8 mmol/L treated with high-dose statins. Extrapolation of study results to the population  
of patients with familial hypercholesterolaemia (FH) in Poland
Table 2. Lipid-lowering therapy prescribed during the study visit in patients with FH6+ (primary care physicians vs. cardiologists)
Per cent of patients
Overall Primary care Cardiologists
Low statin dose 45.1% 56.2% 15.2%
High statin dose 32.8% 22.9% 59.2%
Low statin dose + ezetimibe 0.6% 0.0% 2.8%
High statin dose + ezetimibe 6.8% 6.8% 6.4%
Ezetimibe without statin 0.0% 0.0% 0.0%
Other treatment 5.1% 5.9% 0.0%
No drug therapy 9.6% 8.1% 16.4%
Overall 100% 100% 100%
High statin dose: rosuvastatin ≥ 20 mg or atorvastatin ≥ 40 mg
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cared for by primary care physicians and only 18% of patients 
cared for by cardiologists).
DISCUSSION
In our study, based on a representative sample of physicians 
(primary care physicians, cardiologists, and diabetologists) and 
their patients, we received data describing the population of 
at least probable FH in outpatient care. Estimation of these 
results shows the quality of the diagnosis and treatment of at 
least probable FH in all outpatient care in Poland. 
The first data on the prevalence of FH in the Polish 
population were reported in 2016 with the publication of 
a meta-analysis of six large observational studies that included 
37,889 subjects aged between 20 and 79 years [1]. The di-
agnosis of definite or probable FH was based on the DLCN 
criteria. The prevalence of at least probable FH (score ≥ 6) was 
estimated at 404/100,000 subjects or 0.40% (approximately 
1/250), and was similar to the prevalence in other European 
countries [11–13]. In our study, we estimated that definite or 
probable FH may be present in 136,300 adult patients receiv-
ing outpatient care. Our results are similar to the findings from 
the meta-analysis by Pająk et al. [1], although the latter are for 
the general adult population, and our estimates are for adult 
outpatients. Definite FH (DLCN score > 8) was identified in 
seven cases in the meta-analysis, while we found 51 patients 
with definite FH based on DLCN scoring, amounting to 2.2% 
of the study subjects and translating to about 80,800 adult 
outpatients cared for by primary care physicians, cardiologists, 
and diabetologists in Poland. This difference in the rates of 
definite FH may be related to the fact that as many as half of 
our patients had coronary artery disease, and in some of them 
it was related to severe FH (DLCN score > 8).
Notably, a high rate of probable or definite FH was found 
in Polish patients following an acute coronary syndrome in 
the EUROASPIRE IV study [14]. FH was present in 11.4% of 
the Polish study participants, compared to 8.3% of patients in 
the overall EUROASPIRE IV study population (7044 patients 
from 24 countries aged 18–80 years), including 20.8% of 
patients below 50 years of age. These findings indicate a need 
for the diagnosis of FH (based on the DLCN criteria) among 
patients with premature coronary artery disease and LDL-C 
levels ≥ 4.9 mmol/L (190 mg/dL) admitted to cardiology units 
due to an acute coronary syndrome. Regarding treatment of 
FH, no country-specific data were provided in that publica-
tion, but overall 55% of patients with FH received intensive 
statin therapy.
In addition to estimating the prevalence of FH among 
outpatients, the other major goal of our study was to evalu-
ate the quality of the diagnosis and treatment of FH. It is the 
first Polish study that set these goals in a nationwide sample 
of primary care physicians, cardiologists, and diabetologists 
in Poland. The recent study by Kłosiewicz-Latoszek et al. [15] 
only evaluated adherence to the European Society of Cardiol-
ogy/European Atherosclerosis Society (ESC/EAS) guidelines [8] 
in patients with a previous appropriate diagnosis of FH, 
who were cared for by physicians in a single specialist clinic. 
Thus, the ability to diagnose FH by the participating physi-
cians cannot be compared between our study and the study 
Figure 3. Appropriateness of the diagnosis of familial hypercholesterolaemia (FH) by the study physicians. Extrapolation of the  
study findings to the population of patients with low-density lipoprotein cholesterol (LDL-C) levels > 1.81 mmol/L; DLCN —  
Dutch Lipid Clinic Network
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by Kłosiewicz-Latoszek et al. [15]. In addition, the authors of 
the latter study work in a specialist lipid disorder clinic and 
thus are experts in this area.
Our findings regarding the appropriateness of the diag-
nosis of FH are disturbing. When extrapolated to the overall 
outpatient population in Poland, the diagnosis of FH would be 
confirmed based on the DLCN criteria in 34,000 of 88,000 pa-
tients with the diagnosis of FH declared by the participating 
physicians, and it would not be confirmed by the DLCN criteria 
in the remaining patients. In contrast, among patients without 
the diagnosis of FH by the participating physicians, extrapolated 
to 3,349,035 outpatients nationwide, FH might be diagnosed 
by the DLCN criteria in 90,400 patients. Finally, FH might be 
diagnosed by the DLCN criteria in 11,500 of the estimated 
320,000 patients nationwide in whom the participating physi-
cians declared a lack of data to diagnose or exclude FH. In sum-
mary, FH might be diagnosed in 136,000 adult outpatients in 
Poland, and the extrapolated number of appropriate diagnoses 
of FH by the participating physicians (34,000) is only 25% of 
the overall number of patients with FH (136,300). This gives 
102,000 patients (75%) with FH who remain without the proper 
diagnosis. These data indicate that physicians have inadequate 
knowledge regarding the diagnosis of FH.
In addition, our findings indicate that drug treatment in 
these patients is also inadequate. Despite the high LDL-C lev-
els that always accompany FH, as many as 45.1% of patients 
were prescribed with low statin doses during a study visit, 
including 56.2% of patients treated by primary care physicians 
and 15.2% of patients treated by cardiologists. High statin 
doses were prescribed to 32.8% patients. Thus, the potential 
benefits of statin therapy were not utilised adequately in the 
treatment of FH.
Our study also indicates that even in patients treated 
with high statin doses, high LDL-C levels of ≥ 4.1 mmol/L 
and ≥ 4.9 mmol/L were noted in 59.7% and 42.7% of patients, 
respectively. The ESC/EAS guidelines recommend lowering 
LDL-C level to < 2.6 mmol/L in subjects without cardiovascu-
lar disease and < 1.8 mmol/L in subjects with cardiovascular 
disease [8]. In our study, 88.3% of patients with FH, who re-
ceived high statin doses, had a LDL-C level ≥ 2.6 mmol/L. This 
proportion is much higher compared to the proportion of Pol-
ish patients with coronary artery disease with high LDL-C (9% 
with LDL-C ≥ 4.0 mmol/L and 30% with LDL-C ≥ 4.0 mmol/L) 
despite high-dose statin treatment [16].
The target LDL-C level in patients with FH and cardio-
vascular disease is < 1.8 mmol/L [8]. Our study provided 
no data on the proportion of patients who achieved target 
LDL-C levels. However, among secondary prevention pa-
tients with FH, LDL-C level was ≥ 2.6 mmol/L in 85.7% of 
patients, ≥ 4.9 mmol/L in 43.6% of patients, and ≥ 4.1 mmol/L 
in 52.5% of patients. These proportions may be extrapolated 
to large patient numbers nationwide, as indicated in the results
In the abovementioned retrospective study by Kłosiewicz-
-Latoszek et al. [15], which evaluated patients in a specialist 
clinic, more than half (56.9%) of 222 patients with FH were 
treated with high statin doses, 39.7% received moderate statin 
doses, and 7% received low statin doses. Target LDL-C level 
(< 1.8 mmol/L or < 2.6 mmol/L, depending on the risk level) 
was achieved by 25.2% of patients, regardless of the therapy 
used, including 13.3% of the high-risk patients. These data 
suggest, as might be expected, that treatment of FH in a spe-
cialist lipid disorder clinic is superior to regular outpatient 
care in Poland, as indicated by higher proportions of patients 
receiving high statin doses (56.9% vs. 32.8%) or combined 
statin and ezetimibe therapy (44.6% vs. 7.4%). However, 
even specialist clinic treatment cannot be considered optimal 
because only 25.2% of patients achieved target LDL-C lev-
els. Undertreatment is also an unresolved problem in countries 
such the Netherlands, where only 21% of FH patients reached 
LDL-C level < 2.5 mmol/L [17]. This indicates the need for 
novel therapeutic options in some patients.
Our study findings indicate that the diagnosis and treat-
ment of FH in Poland is suboptimal. Only a small proportion of 
patients received intensive statin therapy or combined therapy. 
The reasons for this are complex and include unawareness of 
a high prevalence of FH and a high cardiovascular risk associ-
ated with FH, in particular coronary risk, low awareness and 
use of the DLCN diagnostic criteria, not using cascade screening 
to identify affected patient family members, low use of avail-
able therapeutic options, and unavailability of new therapeutic 
options (PCSK9 inhibitors) that allow target LDL-C levels to be 
achieved when added to a therapy with a maximum tolerated 
statin dose plus ezetimibe. Such an approach to the treatment 
of FH has been recommended in the ESC/EAS Consensus Paper 
[18] and in the updated National Lipid Association guidelines 
directed for outpatient care [10]. This is justified by observations 
of lower coronary event rates following LDL-C level reduction 
in FH patients treated with statins compared to the pre-statin 
era [19, 20]. New therapeutic options may further improve 
treatment outcomes for this condition.
Our research, by assumption, does not include patients 
who do not use outpatient care, particularly those who do 
not take advice from general practitioners, cardiologists, and 
diabetologists. Detailed data regarding the applied therapy 
and patients’ condition was not collected in reference to 
patients in whom recently noted LDL-C concentration was 
1.8 mmol/L or lower. Moreover, some limitations result from 
the sampling method and the manner of data collection: 
when inviting physicians for the study a quota sampling was 
applied due to the lack of effective use of random sampling. 
Data regarding the use of treatment and patients’ medical 
profile was obtained based on physicians’ declarations (the 
basis for which was data from patients’ medical records) and 
it was not additionally objectively verified. 
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In conclusion: (1) Based on extrapolation of our study 
findings, it may be estimated that at least probable FH (score 
6+ by the DLCN criteria) may be present in 136,300 adult 
outpatients in Poland with LDL-C levels > 1.8 mmol/L. This 
would mean that a relatively large population of Polish pa-
tients still awaits proper diagnosis, prevention, and treatment. 
(2) Among diagnoses of FH declared by the study physicians 
(88,000 cases nationwide), only 39% could be confirmed 
by the DLCN criteria. Among patients with the diagnosis 
of FH6+ based on the DLCN criteria, the diagnosis of FH 
was appropriately made in only 25% of cases, and 75% of 
cases remained undiagnosed despite clinical evidence that 
would allow this diagnosis. The latter translates to about 
102,000 patients receiving outpatient care from primary care 
physicians, cardiologists, and diabetologists. These findings 
indicate a need to educate physicians about the diagnostic 
criteria and the diagnosis of FH. (3) Only 32.8% of patients 
with FH — after weighting and extrapolation — receive high 
statin doses, and LDL-C levels are ≥ 5.0 mmol/L in as many as 
42.7%, and ≥ 4.1 mmol/L in 59.7% of those treated with high 
statin doses. These findings reflect a low level of adherence to 
the recommendations regarding treatment of patients with FH.
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